Combination Therapy with 308-nm Excimer Laser, Compound Glycyrrhizin, and Tacrolimus for Pediatric Facial and Cervical Vitiligo

Background: Vitiligo is a common acquired depigmenting disorder in pediatric dermatology. Facial and cervical involvement is particularly distressing due to cosmetic disfigurement, leading to psychosocial impairment in children and significant psychological burden for parents. Safe and effective treatment strategies to halt disease progression and promote repigmentation are urgently needed. Objective: To evaluate the clinical efficacy, onset of repigmentation, safety, and repigmentation patterns of 308-nm excimer laser combined with oral compound glycyrrhizin and topical 0.03% tacrolimus in children with facial and cervical vitiligo. Methods: A total of 112 pediatric patients were randomized into two groups: treatment group (n=56, 86 lesions) received oral compound glycyrrhizin, topical 0.03% tacrolimus, plus 308-nm excimer laser twice weekly for 16 weeks; control group (n=56, 78 lesions) received compound glycyrrhizin and tacrolimus only. Clinical efficacy, time to initial repigmentation, adverse events, and repigmentation patterns (marginal, follicular, mixed) were assessed. Results: The overall efficacy rate was significantly higher in the treatment group (89.53%) than in controls (70.51%) (p< 0.05). Initial repigmentation occurred earlier in the treatment group (face: 3.12± 0.45 weeks; neck: 3.74± 0.44 weeks) compared with controls (face: 4.08± 0.50 weeks; neck: 4.54± 0.51 weeks, both p< 0.05). Adverse events were rare (3.57%) and self-limited. Repigmentation patterns differed: treatment lesions showed predominantly mixed repigmentation (65.12%), whereas controls were mainly follicular (57.69%). Conclusion: Combination therapy with 308-nm excimer laser, compound glycyrrhizin, and 0.03% tacrolimus is safe and effective for pediatric facial and cervical vitiligo, providing faster repigmentation, higher efficacy, and distinct repigmentation patterns compared with medical therapy alone. Keywords: vitiligo, pediatric, excimer laser, tacrolimus, glycyrrhizin, repigmentation pattern

Authors

Institutions

Publication Details

Journal
Clinical Cosmetic and Investigational Dermatology
Published
2026-03-01
DOI
https://doi.org/10.2147/ccid.s593313
Primary Topic
melanin and skin pigmentation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Combination Therapy with 308-nm Excimer Laser, Compound Glycyrrhizin, and Tacrolimus for Pediatric Facial and Cervical Vitiligo

Yu Qian, YaFen Wu, Siyuan Song, Qian Chen et al.
Clinical Cosmetic and Investigational Dermatology
melanin and skin pigmentation
article

Combination Therapy with 308-nm Excimer Laser, Compound Glycyrrhizin, and Tacrolimus for Pediatric Facial and Cervical Vitiligo

Yu Qian, YaFen Wu, Siyuan Song, Qian Chen, Wei Li, Ting Zhang
article en

Abstract

Background: Vitiligo is a common acquired depigmenting disorder in pediatric dermatology. Facial and cervical involvement is particularly distressing due to cosmetic disfigurement, leading to psychosocial impairment in children and significant psychological burden for parents. Safe and effective treatment strategies to halt disease progression and promote repigmentation are urgently needed. Objective: To evaluate the clinical efficacy, onset of repigmentation, safety, and repigmentation patterns of 308-nm excimer laser combined with oral compound glycyrrhizin and topical 0.03% tacrolimus in children with facial and cervical vitiligo. Methods: A total of 112 pediatric patients were randomized into two groups: treatment group (n=56, 86 lesions) received oral compound glycyrrhizin, topical 0.03% tacrolimus, plus 308-nm excimer laser twice weekly for 16 weeks; control group (n=56, 78 lesions) received compound glycyrrhizin and tacrolimus only. Clinical efficacy, time to initial repigmentation, adverse events, and repigmentation patterns (marginal, follicular, mixed) were assessed. Results: The overall efficacy rate was significantly higher in the treatment group (89.53%) than in controls (70.51%) (p< 0.05). Initial repigmentation occurred earlier in the treatment group (face: 3.12± 0.45 weeks; neck: 3.74± 0.44 weeks) compared with controls (face: 4.08± 0.50 weeks; neck: 4.54± 0.51 weeks, both p< 0.05). Adverse events were rare (3.57%) and self-limited. Repigmentation patterns differed: treatment lesions showed predominantly mixed repigmentation (65.12%), whereas controls were mainly follicular (57.69%). Conclusion: Combination therapy with 308-nm excimer laser, compound glycyrrhizin, and 0.03% tacrolimus is safe and effective for pediatric facial and cervical vitiligo, providing faster repigmentation, higher efficacy, and distinct repigmentation patterns compared with medical therapy alone. Keywords: vitiligo, pediatric, excimer laser, tacrolimus, glycyrrhizin, repigmentation pattern

Clinical Cosmetic and Investigational DermatologyVol. Volume 19
Baylor College of Medicine (US), Soochow University (CN)
Good health and well-being
Openalex Percentile: Top 8%
melanin and skin pigmentation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.